Learn more about Peter Attia’s digital program
#213 ‒ Liquid biopsies and cancer detection | Max Diehn, M.D. Ph.D.
“I was frustrated by not being able to diagnose a recurrence earlier.” —Max Diehn
#181 – Robert Gatenby, M.D.: Viewing cancer through an evolutionary lens and why this offers a radically different approach to treatment
“For a century we’ve been looking for magic bullets, but maybe all we need is a series of pretty good bullets.” —Bob Gatenby
A few things worth sharing: 11-29-2020
Novel cancer therapy 17-year roundup; AI designed to deceive
#133 – Vinay Prasad, M.D., M.P.H: Hallmarks of successful cancer policy
“The more you practice medicine, the more you realize that it’s an art. . .You’re going to have to make decisions today with less than perfect information.” —Vinay Prasad
#121 – Azra Raza, M.D.: Why we’re losing the war on cancer
“We are living in an era of the most sophisticated technological advances possible, and yet the treatment of cancer is paleolithic.” — Azra Raza
#114 – Eileen White, Ph.D.: Autophagy, fasting, and promising new cancer therapies
“I would like to translate what we’ve learned about the role of autophagy in cancer and that involves developing small molecules to inhibit autophagy for cancer therapy.” — Eileen White
#110 – Lew Cantley, Ph.D.: Cancer metabolism, cancer therapies, and the discovery of PI3K
“If I get a result that suddenly doesn’t make sense, to me that’s more exciting. . .if you figure out why it didn’t work and what was wrong, then that’s where most breakthroughs come from.” — Lew Cantley
#62 – Keith Flaherty, M.D.: Deep dive into cancer— History of oncology, novel approaches to treatment, and the exciting and hopeful future
“We can’t keep hitting the same pillar and expect that we’re going to cure cancer. . .we need the activators of the immune system, we need the inhibitors of the activated oncogenes, we need the drugs that target epigenetic regulators, and we need the metabolic switch regulators.” — Keith Flaherty